Psoriasiform eruption induced by infliximab

被引:93
作者
Verea, MM
Del Pozo, J
Yebra-Pimentel, MT
Porta, A
Fonseca, E
机构
[1] Hosp Juan Canalejo, Dept Dermatol, La Coruna 15006, Spain
[2] Hosp Juan Canalejo, Dept Pathol, La Coruna 15006, Spain
[3] Hosp Juan Canalejo, Dept Pharm, La Coruna 15006, Spain
关键词
infliximab; psoriasiform eruption;
D O I
10.1345/aph.1C477
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To report a case of psoriasiform eruption induced by infliximab. CASE SUMMARY: A 46-year-old woman with enterocutaneous fistula secondary to Crohn's disease developed pruriginous, erythematous, desquamative plaques on her elbows, knees, hands, and buttocks after receiving the second and third doses of intravenous infliximab. Histologic examination showed a lichenoid pattern. No new cutaneous lesions appeared after cessation of infliximab therapy. DISCUSSION: Several cutaneous reactions secondary to infliximab, a monoclonal antibody against tumor necrosis factor-alfa, have been described. Psoriasiform dermatitis has not been reported as a cutaneous reaction to infliximab, but there have been several previous reports of psoriasiform dermatitis secondary to other drugs. An objective causality assessment revealed that the adverse event was probable. CONCLUSIONS: This is the first report of a clinico-pathologic dissociated pattern of cutaneous reaction showing a histopathologic picture of lichenoid dermatitis resulting from infliximab treatment.
引用
收藏
页码:54 / 57
页数:4
相关论文
共 26 条
[1]   Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].
Baert, F ;
Noman, M ;
Vermeire, S ;
Van Assche, G ;
D'Haens, G ;
Carbonez, A ;
Rutgeerts, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608
[2]   Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications [J].
Baert, FJ ;
Rutgeerts, PR .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 1999, 14 (01) :47-51
[3]   Antibodies to tumour necrosis factor α as treatment for Crohn's disease [J].
Bell, S ;
Kamm, MA .
LANCET, 2000, 355 (9207) :858-860
[4]   The relationship between infliximab treatment and lymphoma in Crohn's disease [J].
Bickston, SJ ;
Lichtenstein, GR ;
Arseneau, KO ;
Cohen, RB ;
Cominelli, F .
GASTROENTEROLOGY, 1999, 117 (06) :1433-1437
[5]   Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis [J].
Chan, ATY ;
Cleeve, V ;
Daymond, TJ .
POSTGRADUATE MEDICAL JOURNAL, 2002, 78 (915) :47-48
[6]   Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial [J].
Chaudhari, U ;
Romano, P ;
Mulcahy, LD ;
Dooley, LT ;
Baker, DG ;
Gottlieb, AB .
LANCET, 2001, 357 (9271) :1842-1847
[7]   Mechanisms of disease: Cytokine pathways and joint inflammation in rheumatoid arthritis. [J].
Choy, EHS ;
Panayi, GS .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (12) :907-916
[8]   Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy [J].
Devos, SA ;
Van Den Bossche, N ;
De Vos, M ;
Naeyaert, JM .
DERMATOLOGY, 2003, 206 (04) :388-390
[9]   REPEATED THERAPY WITH MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) IN PATIENTS WITH RHEUMATOID-ARTHRITIS [J].
ELLIOTT, MJ ;
MAINI, RN ;
FELDMANN, M ;
LONGFOX, A ;
CHARLES, P ;
BIJL, H ;
WOODY, JN .
LANCET, 1994, 344 (8930) :1125-1127
[10]   Treatment of Crohn's disease with infliximab [J].
Garnett, WR ;
Yunker, N .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2001, 58 (04) :307-316